There are many recipes for a soaring stock price.
Here's one I like a lot...
1. A company that taps into previously prohibited yet well-established markets
2. Excellent leadership skills
3. A killer execution strategy
And that's precisely what we've been seeing with a firm I mentioned most recently back in mid-July.
At that time, I told you how this company became the world's first seed-to-sale cannabis outfit ever to make its initial public offering on a major U.S. stock exchange.
During its IPO, the company raised about $164 million, which it's plowing directly into building out its cannabis cultivation and processing capacity, among other projects.
And it just secured an important new "gig" that sent its shares soaring as high as 32% yesterday...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
This Company Started Strong... and Got Much, Much Stronger
Tilray Inc. (NASDAQ: TLRY), has been tearing up the markets pretty much ever since its summer debut.
I'm not the least bit surprised.
Drop EVERYTHING and See This (There Could Be Billions at Stake): A critical piece of legislation is expected to trigger BILLIONS of dollars flooding into tiny cannabis companies. When this happens, share prices could soar up to five or even 10 times - and if you know what to do, you could be launched all the way to millionaire status... Full Story
Though it got a late start in the IPO game, Tilray has a long history of being a "first mover" in the legal marijuana market. In fact, it was the first cannabis company to distribute its marijuana at home and abroad.
And since its debut on the Nasdaq July 19, Tilray's stock price has advanced a staggering 398%.
To be blunt, this is the kind of explosive performance you might expect from a tiny, volatile micro cap, but Tilray is a very well established, New York--listed company sporting a $13.8 billion market cap.
In the second quarter, Tilray reported 95.2% revenue growth, to $9.7 million.
Now, while this revenue growth represents just the start as a public company for this cannabis pioneer, it also points to two major upcoming catalysts.
Let me explain...
See, in a statement about its latest earnings figures, Tilray said its revenue surge in recent months can be attributed partly to increased patient demand for medical marijuana in its home market. And that demand is only going to expand as medical marijuana gains wider acceptance.
By This Time Next Year, You Could Be on the Path to $2 Million: One new law is expected to change everything for the legal cannabis industry - and maybe for you. That's because we're revealing three marijuana companies that could help put $2 million (or more) in your pocket by summer 2019... Details Here
But there's much more going on with this cannabis producer. The firm also sells its products into 12 countries on five continents. It recently completed export agreements in Argentina, South Africa, and the United Kingdom.
And now it looks like Tilray is coming to another important world weed market: the United States.
Yes, you read that right.
Tilray Could Be the Pot Stock That Conquers the World
Yesterday, shares of Tilray went positively stratospheric when the company announced it had secured approval from the U.S. Drug Enforcement Administration (DEA) to import marijuana into the United States for medical research.
Now, the approval, under the terms of which Tilray will supply marijuana to the University of San Diego Center for Medicinal Cannabis Research, isn't quite an export agreement, but it is extremely significant.
That's because the DEA has long been resistant to the idea that marijuana has any medicinal potential at all. After all, at the federal level, cannabis is still a Schedule 1 drug, in the same class as heroin or LSD.
It's early yet - and it's important we don't read too much into the DEA's position - but this could mean the nation's drug cops are serious about their stated goal of "doing more" to assist American researchers with almost painfully limited access to cannabis for study.
Investors are enthusiastic about the prospects, to put it mildly.
I am, too. Because as insanely profitable as Tilray's been for us, even bigger things could be in store.
Tilray is also at the forefront of the medical cannabis industry, boasting a stable of cannabidiol-based products for patients suffering from chronic pain, arthritis, nausea, and other maladies.
That puts it in a prime position to take on the $57 billion international market Arcview Market Research expects by 2027.
Tilray could realize multiples of its current gains by then - and you want to make sure you're along for the ride.
CLICK TO WATCH: Critical Briefing on the New Marijuana Millionaires Law
A critical update to cannabis legislation is going into effect in a matter of days.
When it does, it will open the door for tens of billions of dollars to pour into the sector…
… and folks who take the opportunity seriously could easily become the next generation of this nation's millionaires.
That's why Money Morning's executive publisher is inviting you to view an urgent briefing right now to get all the critical details.
Click here to watch the briefing now.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.